Skip to content

Katsuyuki Kaneda

9 papers in the library · publishing 2018-2025

Papers

Sort Most recent Most cited

L-type voltage-dependent calcium channels in the ventromedial orbitofrontal and prefrontal cortices mediate the inhibitory effects of (S)-ketamine but not (R)-ketamine on marble burying in male mice

European Journal of Pharmacology October 25, 2025 Satoshi Deyama, Kenji Mishiro, Munetaka Kunishima et al.

Glutamatergic abnormalities in several brain regions, including the ventromedial orbitofrontal cortex (vmOFC) and prefrontal cortex (vmPFC), have been implicated in the pathophysiology of obsessive-compulsive disorder (OCD). (R, S)-ketamine, an N-methyl-D-aspartate (NMDA) receptor antagonist, and enantiopure (S)-ketamine may have therapeutic effects in patients and animal models of OCD....

Effects of 3,4-methylenedioxymethamphetamine on neural activity in the nucleus accumbens of male mice engaged in social behavior.

Neuropsychopharmacology Reports March 1, 2025 Naoya Nishitani, Yuki Sasaki, Katsuyuki Kaneda

3,4-methylenedioxymethamphetamine (MDMA), a commonly abused recreational drug, induces prosocial effects such as increased sociability and empathy. The nucleus accumbens (NAc) has been suggested to play a crucial role in these MDMA-mediated prosocial effects. However, the relationship between social behavior and NAc neural activity, and the effects of MDMA on this relationship, remain unknown....

DOI: 10.1002/npr2.12510 (opens in new tab) Full text (opens in new tab) 3,4‐methylenedioxymethamphetamine Calcium imaging Fiber photometry Nucleus accumbens +4

Role of 5-HT1A receptors in the basolateral amygdala on 3,4-methylenedioxymethamphetamine-induced prosocial effects in mice.

European Journal of Pharmacology March 10, 2023 Hirohito Esaki, Yuki Sasaki, Naoya Nishitani et al.

3,4-methylenedioxymethamphetamine (MDMA), a recreational drug, induces euphoric sensations and psychosocial effects, such as increased sociability and empathy. Serotonin, also called 5-hydroxytryptamine (5-HT), is a neurotransmitter that has been associated with MDMA-induced prosocial effects. However, the detailed neural mechanisms remain elusive. In the present study, we investigated whether...

DOI: 10.1016/j.ejphar.2023.175653 (opens in new tab) MDMA Animals Mice, inbred icr N-methyl-3,4-methylenedioxyamphetamine +8

Role of neurotrophic and growth factors in the rapid and sustained antidepressant actions of ketamine.

Neuropharmacology November 17, 2022 Satoshi Deyama, Katsuyuki Kaneda

The neurotrophic hypothesis of depression proposes that reduced levels of brain-derived neurotrophic factor (BDNF) and vascular endothelial growth factor (VEGF) contribute to neuronal atrophy or loss in the prefrontal cortex (PFC) and hippocampus and impaired hippocampal adult neurogenesis, which are associated with depressive symptoms. Chronic, but acute, treatment with typical monoaminergic...

IGF-1 release in the medial prefrontal cortex mediates the rapid and sustained antidepressant-like actions of ketamine

Translational Psychiatry May 17, 2022 Satoshi Deyama, M. Kondo, Shoichi Shimada et al.

Ketamine, an N-methyl-D-aspartate receptor antagonist, exerts rapid and sustained antidepressant actions. Preclinical studies demonstrated that the release of brain-derived neurotrophic factor (BDNF) and vascular endothelial growth factor in the medial prefrontal cortex (mPFC) is essential for the antidepressant-like effects of ketamine. However, the role of other neurotrophic factors in the...

Roles of TRPC3 and TRPC6 in the medial prefrontal cortex in the antidepressant-like actions of ketamine

Proceedings for Annual Meeting of The Japanese Pharmacological Society 2021 Satoshi Deyama, Katsuyuki Kaneda

The antidepressant actions of the NMDA receptor antagonist ketamine require activity-dependent release of brain-derived neurotrophic factor (BDNF) in the medial prefrontal cortex (mPFC). Our recent study shows a similar requirement for vascular endothelial growth factor (VEGF). Previous studies have reported that both BDNF and VEGF activate TRPC3 and TRPC6 via diacylglycerol production, and...

Differential sensitivity to detect prosocial effects of 3,4‐methylenedioxymethamphetamine (MDMA) in different social approach paradigms in mice

Neuropsychopharmacology Reports September 1, 2020 Satoko Mukai, Sao Nakada, Hikari Kamada et al.

AbstractA recreational drug, 3,4‐methylenedioxymethamphetamine (MDMA), has prosocial effects including increased sociability, enhancement of trust feelings, and empathy. Although several methods, such as the social interaction and three chamber tests, have been used, the neural mechanisms underlying the prosocial effects have not been well understood. In the present study, based on a social...

Effects of the synthetic cannabinoid 5F-AMB on anxiety and recognition memory in mice.

Psychopharmacology July 1, 2019 Shiho Ito, Satoshi Deyama, Masaki Domoto et al.

N-[[1-(5-fluoropentyl)-1H-indazol-3-yl]carbonyl]-L-valine methyl ester (5F-AMB) is a synthetic cannabinoid that has been distributed recently. Although inhalation of 5F-AMB produces adverse effects, such as impaired memory and disturbed consciousness, in humans, the psychopharmacological effects of 5F-AMB in rodents have not been investigated. We first examined the effects of intraperitoneal...

DOI: 10.1007/s00213-019-05222-2 (opens in new tab) Full text (opens in new tab) 5f-amb Designer drug Medial prefrontal cortex Synthetic cannabinoids

The synthetic cannabinoid 5F-AMB changes the balance between excitation and inhibition of layer V pyramidal neurons in the mouse medial prefrontal cortex.

Psychopharmacology August 1, 2018 Masaki Domoto, Hitoki Sasase, Shintaro Wada et al.

5F-AMB is one of the synthetic cannabinoids (SCs) designed to potentiate the ability to activate cannabinoid 1 (CB1) receptors and is abused worldwide. Although inhalation of 5F-AMB elicits serious adverse effects including impaired memory and consciousness, it is not known whether and how 5F-AMB affects the activity of pyramidal neurons in the medial prefrontal cortex (mPFC), a brain region...

DOI: 10.1007/s00213-018-4933-5 (opens in new tab) Full text (opens in new tab) 5f-amb Cb1 receptor Designer drug Medial prefrontal cortex +1